Medtronic PLC $MDT Shares Purchased by Auxano Advisors LLC

Auxano Advisors LLC raised its position in Medtronic PLC (NYSE:MDT) by 5.0% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 16,548 shares of the medical technology company’s stock after buying an additional 783 shares during the period. Auxano Advisors LLC’s holdings in Medtronic were worth $1,442,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of MDT. 1248 Management LLC purchased a new position in Medtronic in the 1st quarter valued at $26,000. Twin Tree Management LP purchased a new position in Medtronic during the first quarter worth about $29,000. Activest Wealth Management lifted its holdings in Medtronic by 3,577.8% in the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock valued at $30,000 after acquiring an additional 322 shares during the last quarter. Investment Management Corp VA ADV lifted its stake in shares of Medtronic by 144.2% in the 1st quarter. Investment Management Corp VA ADV now owns 403 shares of the medical technology company’s stock valued at $36,000 after purchasing an additional 238 shares during the last quarter. Finally, GFG Capital LLC purchased a new position in Medtronic during the second quarter worth about $36,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

Medtronic Trading Down 0.7%

MDT opened at $100.12 on Thursday. The company has a debt-to-equity ratio of 0.54, a quick ratio of 1.50 and a current ratio of 2.01. Medtronic PLC has a one year low of $79.29 and a one year high of $102.59. The company has a market cap of $128.42 billion, a P/E ratio of 27.58, a PEG ratio of 2.42 and a beta of 0.77. The business’s 50-day simple moving average is $94.80 and its 200-day simple moving average is $90.70.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The firm had revenue of $8.96 billion during the quarter, compared to the consensus estimate of $8.86 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. As a group, equities research analysts expect that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms have recently commented on MDT. The Goldman Sachs Group set a $111.00 price target on Medtronic and gave the stock a “neutral” rating in a research report on Wednesday. Cowen restated a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Needham & Company LLC reaffirmed a “hold” rating on shares of Medtronic in a research report on Thursday, August 14th. JPMorgan Chase & Co. lifted their price objective on Medtronic from $90.00 to $100.00 and gave the company a “neutral” rating in a research note on Thursday, November 13th. Finally, Piper Sandler restated a “neutral” rating on shares of Medtronic in a research note on Friday, November 14th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and twelve have issued a Hold rating to the company. Based on data from MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and a consensus target price of $108.50.

Insider Buying and Selling at Medtronic

In related news, EVP Harry Skip Kiil sold 8,605 shares of the stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the transaction, the executive vice president directly owned 35,615 shares of the company’s stock, valued at $3,261,621.70. This trade represents a 19.46% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director William R. Jellison bought 2,500 shares of Medtronic stock in a transaction dated Monday, August 25th. The stock was purchased at an average cost of $92.37 per share, with a total value of $230,925.00. Following the completion of the acquisition, the director directly owned 5,000 shares in the company, valued at approximately $461,850. The trade was a 100.00% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Corporate insiders own 0.26% of the company’s stock.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.